The first patient in a Phase II pilot study of a combination of Novocure's Optune tumor-treating fields delivery device and Roche Holding's Avastin has been enrolled. The 85-subject trial, which has a primary endpoint of overall survival at six months, seeks to assess use of the combined therapy for treating patients with refractory recurrent glioblastoma.
Study begins for Novocure's Optune device, Roche's Avastin
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.